U.S. Hormone Replacement Therapy Market Size, Share & Trends Analysis Report By Product, By Route Of Administration, By Disease Type (Menopause, Hypothyroidism, Male Hypogonadism), And Segment Forecasts, 2020 - 2027

November 2020 | 70 pages | ID: U8490EF76BDBEN
Grand View Research, Inc.

Abstracts

This report can be delivered to the clients within 72 Business Hours

U.S. Hormone Replacement Therapy Market Growth & Trends

The U.S. hormone replacement therapy market size is expected to reach USD 16.39 billion by 2027, according to a new study by Grand View Research Inc. The market is expected to expand at a CAGR of 6.1% from 2020 to 2027. The growth in the market is largely attributable to the technological advancements in the drug delivery systems coupled with the rising prevalence of hormonal disorders.

In February 2020, Clarus Therapeutics, Inc. announced the FDA approval of Jatenzo (testosterone undecanoate) capsules for the treatment of testosterone deficiency (hypogonadism). Jatenzo is the first and only oral soft gel of testosterone approved by the U.S. FDA. The product however has not yet been commercialized. Innovation and introduction of novel products may fuel market growth.

In addition, injectable testosterone and transdermal products have been the preferred treatment for male hypogonadism. In April 2016, Aytu BioScience, Inc. entered into the market with a long-term, exclusive license agreement for Natesto with Acerus Pharmaceuticals Corporation. Natesto is the first nasal formulation of testosterone approved by the U.S. FDA for the indication of hypogonadism.

Companies are taking the initiative to raise awareness regarding the diseases and thereby increase the adoption of their products. For instance, in September 2020, AbbVie introduced a direct-to-patient pharmacy program that offers Synthroid to be delivered at a patient’s doorstep. Synthroid Delivers Program initiative may help the company increase revenue during the pandemic while supporting people in following home quarantine. However, the duration of hormone replacement therapies differs from patient to patient. This treatment is generally expensive, which is a key parameter for limiting the market growth.

U.S. Hormone Replacement Therapy Market Report Highlights

• By product, the estrogen and progesterone replacement therapy segment held the largest share in 2019 followed by the thyroid replacement therapy segment
• In August 2020, Novo Nordisk A/S received the U.S. FDA approval for its HGH replacement therapy product Sogroya (somapacitan-beco). This product is administered once a week through a subcutaneous route in adults diagnosed with growth hormone deficiency
• The parathyroid hormone segment is anticipated to witness the fastest growth over the forecast period due to the rising adoption of the product for the treatment of hypoparathyroidism. According to the National Organization for Rare Disease, around 70,000 people in the U.S. have hypoparathyroidism
• The oral segment is anticipated to dominate the market on the basis of route of administration. However, certain notable adverse effects of estrogen-based drugs are expected to reduce the consumption rate, which may impede segment growth
• The parenteral segment is expected to witness the fastest growth over the forecast period. Rapid technological advancements in the parenteral mode of administration, such as pen-based drug delivery and longer-acting human growth hormone products are anticipated to improve patient compliance and facilitate ease of administration, thereby propelling segment growth over the forecast period
• The menopause segment may dominate the market over the forecast period due to the rising incidence, and treatment rates for vasomotor symptoms and vaginal atrophy in the post-menopausal women

Contents

CHAPTER 1 METHODOLOGY

1.1 Market segmentation
  1.1.1 Estimates and Forecast Timeline
1.2 Research Methodology
1.3 Information procurement
  1.3.1 Purchased Database
  1.3.2 GVR’s Internal Database
  1.3.3 Secondary Sources
  1.3.4 Primary Research
  1.3.5 Details of Primary Research
1.4 Information or Data Analysis
  1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
  1.6.1 Commodity Flow Analysis
    1.6.1.1 Approach 1: Commodity Flow Approach
    1.6.1.2 Approach 2: Country-wise market estimation using the bottom-up approach
1.7 U.S. Market: CAGR Calculation
1.8 Research Assumptions
1.9 List of Secondary Sources
1.10 List of Primary Sources
1.11 Objectives
  1.11.1 Objective
  1.11.2 Objective
1.12 List of Abbreviations

CHAPTER 2 EXECUTIVE SUMMARY

2.1 Market Snapshot

CHAPTER 3 INDUSTRY OUTLOOK

3.1 Market Segmentation
3.2 Penetration & Growth Prospect Mapping
3.3 Regulatory and Reimbursement Framework
3.4 Market Variable Analysis
  3.4.1 Market driver analysis
    3.4.1.1 Increase in the number of patients undergoing Hormone Replacement Therapy
    3.4.1.2 Rising prevalence of hormonal disorders
    3.4.1.3 Technological developments in drug delivery systems
  3.4.2 Market restraint analysis
    3.4.2.1 High cost of treatment
    3.4.2.2 Risk of side effects
3.5 Industry Analysis Tools
  3.5.1 PESTEL Analysis
  3.5.2 Porter’s five forces analysis
3.6 Major Deals and Strategic Alliances Analysis
  3.6.1 New Product Launch
  3.6.2 Mergers and Acquisitions
  3.6.3 Promotional Agreements & Joint Ventures
  3.6.4 Conferences and Campaigns
3.7 Pipeline Analysis

CHAPTER 4 U.S. HORMONE REPLACEMENT THERAPY MARKET: PRODUCT SEGMENT ANALYSIS

4.1 U.S. HRT Market: Product Movement Analysis
4.2 Estrogen & Progesterone Replacement Therapy
  4.2.1 Estrogen & Progesterone replacement therapy market, 2016 - 2027 (USD Million)
4.3 Human Growth Hormone (HGH) Replacement Therapy
  4.3.1 HGH replacement therapy market, 2016 - 2027 (USD Million)
4.4 Thyroid Hormone Replacement Therapy
  4.4.1 Thyroid hormone replacement therapy market, 2016 - 2027 (USD Million)
4.5 Testosterone Replacement Therapy
  4.5.1 Testosterone replacement therapy market, 2016 - 2027 (USD Million)
4.6 Parathyroid Hormone
  4.6.1 Parathyroid Hormone market, 2016 - 2027 (USD Million)

CHAPTER 5 U.S. HORMONE REPLACEMENT THERAPY: ROUTE OF ADMINISTRATION SEGMENT ANALYSIS

5.1 U.S. HRT Market: Route of Administration Movement Analysis
5.2 Oral
  5.2.1 Oral market, 2016 - 2027 (USD Million)
5.3 Parenteral
  5.3.1 Parenteral market, 2016 - 2027 (USD Million)
5.4 Transdermal
  5.4.1 Transdermal market, 2016 - 2027 (USD Million)
5.5 Others
  5.5.1 Others market, 2016 - 2027 (USD Million)

CHAPTER 6 U.S. HORMONE REPLACEMENT THERAPY MARKET: DISEASE TYPE SEGMENT ANALYSIS

6.1 U.S. HRT Market: Disease Type Movement Analysis
6.2 Menopause
  6.2.1 Menopause market, 2016 - 2027 (USD Million)
6.3 Hypothyroidism
  6.3.1 Hypothyroidism market, 2016 - 2027 (USD Million)
6.4 Male Hypogonadism
  6.4.1 Male Hypogonadism market, 2016 - 2027 (USD Million)
6.5 Growth Hormone Deficiency
  6.5.1 Growth Hormone Deficiency market, 2016 - 2027 (USD Million)
6.6 Hypoparathyroidism
  6.6.1 Hypoparathyroidism, 2016 - 2027 (USD Million)

CHAPTER 7 HORMONE REPLACEMENT THERAPY MARKET - COMPETITIVE ANALYSIS

7.1 Company Categorization
  7.1.1 Market Differentiators
  7.1.2 Innovators
  7.1.3 Market Leaders
7.2 Vendor Landscape
  7.2.1 List of key distributors and channel partners
  7.2.2 Key customers
7.3 Heat map analysis
7.4 Public Companies
  7.4.1 Key company analysis, 2019
  7.4.2 Company market position analysis
7.5 Company Profiles
  7.5.1 Bayer AG
    7.5.1.1 Company Overview
    7.5.1.2 Financial Performance
    7.5.1.3 Product Benchmarking
    7.5.1.4 Strategic Initiatives
  7.5.2 Pfizer, Inc.
    7.5.2.1 Company Overview
    7.5.2.2 Financial Performance
    7.5.2.3 Product Benchmarking
    7.5.2.4 Strategic Initiatives
  7.5.3 Merck & Co., Inc.
    7.5.3.1 Company Overview
    7.5.3.2 Financial Performance
    7.5.3.3 Product Benchmarking
    7.5.3.4 Strategic Initiatives
  7.5.4 Abbott
    7.5.4.1 Company Overview
    7.5.4.2 Financial Performance
    7.5.4.3 Product Benchmarking
    7.5.4.4 Strategic Initiatives
  7.5.5 Mylan N.V.
    7.5.5.1 Company Overview
    7.5.5.2 Financial Performance
    7.5.5.3 Product Benchmarking
    7.5.5.4 Strategic Initiatives
  7.5.6 Novo Nordisk A/S
    7.5.6.1 Company Overview
    7.5.6.2 Financial Performance
    7.5.6.3 Product Pipeline
    7.5.6.4 Strategic Initiatives
  7.5.7 Eli Lilly and Company
    7.5.7.1 Company Overview
    7.5.7.2 Financial Performance
    7.5.7.3 Product Benchmarking
    7.5.7.4 Strategic Initiatives
  7.5.8 F. Hoffmann-La Roche Ltd. (Genentech)
    7.5.8.1 Company Overview
    7.5.8.2 Financial Performance
    7.5.8.3 Product Benchmarking
  7.5.9 Noven Pharmaceuticals, Inc. (Hisamitsu Pharmaceutical Co., Inc.)
    7.5.9.1 Company Overview
    7.5.9.2 Financial Performance
    7.5.9.3 Product Benchmarking
    7.5.9.4 Strategic Initiatives
  7.5.10 ASCEND Therapeutics US, LLC. (Besins Healthcare)
    7.5.10.1 Company Overview
    7.5.10.2 Product Benchmarking
    7.5.10.3 Strategic Initiatives
  7.5.11 AbbVie Inc.
    7.5.11.1 Company Overview
    7.5.11.2 Financial Performance
    7.5.11.3 Product Benchmarking
    7.5.11.4 Strategic Initiatives

List Of Tables

LIST OF TABLES

TABLE 1 List of secondary sources
TABLE 2 List of Abbreviation
TABLE 3 Regulatory framework
TABLE 4 Eligibility table for menopause treatment services
TABLE 5 Eligibility table for hormone replacement therapy
TABLE 6 Leading market players are anticipated to witness the highest growth
TABLE 7 List of key distributors and Compounding Pharmacies
TABLE 8 Key Company Analysis
TABLE 9 U.S. Hormone Replacement Therapy Market, By product, 2016 - 2027 (USD Million)
TABLE 10 U.S. Hormone Replacement Therapy Market, By route of administration, 2016 - 2027 (USD Million)
TABLE 11 U.S. Hormone Replacement Therapy Market, By disease type, 2016 - 2027 (USD Million)

List Of Figures

LIST OF FIGURES

Fig. 1 U.S. Hormone Replacement Therapy Market Segmentation
Fig. 2 Market research process
Fig. 3 Information procurement
Fig. 4 Primary Research Pattern
Fig. 5 Market research approaches
Fig. 6 Value-chain-based sizing & forecasting
Fig. 7 QFD modeling for market share assessment
Fig. 8 Market formulation & validation
Fig. 9 Market summary
Fig. 10 U.S. HRT Market Segmentation
Fig. 11 Penetration & Growth Prospect Mapping
Fig. 12 Market Driver Impact Analysis (Current & future impact)
Fig. 13 Market Restraint Impact Analysis (Current & future impact)
Fig. 14 PESTEL Analysis
Fig. 15 Porter’s Five Forces Analysis
Fig. 16 U.S. HRT market product outlook: Key takeaways
Fig. 17 U.S. HRT Market: Product Movement Analysis
Fig. 18 Estrogen & Progesterone Replacement Therapy Market, 2016 - 2027 (USD Million)
Fig. 19 HGH Replacement Therapy Market, 2016 - 2027 (USD Million)
Fig. 20 Thyroid Hormone Replacement Therapy Market, 2016 - 2027 (USD Million)
Fig. 21 Testosterone Replacement Therapy Market, 2016 - 2027 (USD Million)
Fig. 22 Parathyroid Hormone Market, 2016 - 2027 (USD Million)
Fig. 23 U.S. HRT Market Route of Administration Outlook: Key takeaways
Fig. 24 U.S. HRT Market: Route of Administration Movement Analysis
Fig. 25 Oral Market, 2016 - 2027 (USD Million)
Fig. 26 Parenteral Market, 2016 - 2027 (USD Million)
Fig. 27 Transdermal Market, 2016 - 2027 (USD Million)
Fig. 28 Others Market, 2016 - 2027 (USD Million)
Fig. 29 U.S. HRT Market Disease Type Outlook: Key takeaways
Fig. 30 U.S. HRT Market: Disease Type Movement Analysis
Fig. 31 Menopause Market, 2016 - 2027 (USD Million)
Fig. 32 Hypothyroidism Market, 2016 - 2027 (USD Million)
Fig. 33 Male Hypogonadism Market, 2016 - 2027 (USD Million)
Fig. 34 Growth Hormone Deficiency Market, 2016 - 2027 (USD Million)
Fig. 35 Hypoparathyroidism, 2016 - 2027 (USD Million)
Fig. 36 Market differentiators
Fig. 37 Heat map analysis